Get the Stockscreener App
6.4401
1.28%
-0.0899
Taysha Gene Therapies Inc stock is traded at $6.4401, with a volume of 884.10K.
It is down -1.28% in the last 24 hours and up +17.21% over the past month.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
See More
Previous Close:
$6.53
Open:
$6.45
24h Volume:
884.10K
Relative Volume:
0.30
Market Cap:
$1.85B
Revenue:
$7.47M
Net Income/Loss:
$-129.88M
P/E Ratio:
-16.25
EPS:
-0.3962
Net Cash Flow:
$-115.33M
1W Performance:
-4.21%
1M Performance:
+17.21%
6M Performance:
+22.56%
1Y Performance:
+163.13%
1-Day Range:
$6.245
$6.565
1-Week Range:
$6.245
$7.12
52-Week Range:
$2.33
$7.30
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Name
Taysha Gene Therapies Inc
Sector
Industry
Phone
(214) 612-0000
Address
3000 PEGASUS PARK DRIVE, DALLAS
Compare TSHA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
6.435 | 1.96B | 7.47M | -129.88M | -115.33M | -0.3962 |
VRTX
Vertex Pharmaceuticals Inc
|
527.99 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
647.54 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
926.19 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.63 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.17 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Initiated | Raymond James | Strong Buy |
| Jul-11-25 | Initiated | BofA Securities | Buy |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Apr-09-24 | Initiated | Piper Sandler | Overweight |
| Feb-01-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-27-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-22 | Downgrade | Goldman | Buy → Neutral |
| Mar-09-22 | Initiated | Robert W. Baird | Outperform |
| Mar-01-22 | Initiated | Wells Fargo | Overweight |
| Feb-18-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | Guggenheim | Buy |
| Jul-16-21 | Initiated | Needham | Buy |
| Jun-24-21 | Initiated | Truist | Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Jun-09-21 | Initiated | Wedbush | Outperform |
| Jun-08-21 | Initiated | JMP Securities | Mkt Outperform |
| May-19-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-11-21 | Resumed | Jefferies | Buy |
| Feb-24-21 | Initiated | William Blair | Outperform |
| Jan-05-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-20 | Initiated | Chardan Capital Markets | Buy |
| Oct-19-20 | Initiated | Goldman | Buy |
| Oct-19-20 | Initiated | Jefferies | Buy |
| Oct-19-20 | Initiated | Morgan Stanley | Overweight |
View All
Taysha Gene Therapies Inc Stock (TSHA) Latest News
Citizens reiterates Taysha Gene Therapies stock rating on therapy progress By Investing.com - Investing.com Canada
A Quick Look at Today's Ratings for Taysha Gene Therapies(TSHA.US), With a Forecast Between $12 to $15 - Moomoo
Enterprise value to EBITDA forward of Taysha Gene Therapies, Inc. – NASDAQ:TSHA - TradingView
TSHA Maintained by Needham -- Price Target Holds at $12.00 - GuruFocus
Enterprise value to EBITDA forward of Taysha Gene Therapies, Inc. – BOATS:TSHA - TradingView
Price to sales forward of Taysha Gene Therapies, Inc. – NASDAQ:TSHA - TradingView
TSHA Maintained by Baird -- Price Target Raised to $15.00 - GuruFocus
Taysha: 'Buy' On Interim Analysis Of TSHA-102 First Half 2027 And Broad Label Potential - Seeking Alpha
symbol__ Stock Quote Price and Forecast - CNN
Price to sales forward of Taysha Gene Therapies, Inc. – BOATS:TSHA - TradingView
Price to book forward of Taysha Gene Therapies, Inc. – NASDAQ:TSHA - TradingView
Price to earnings forward of Taysha Gene Therapies, Inc. – BOATS:TSHA - TradingView
Taysha Gene Therapies, Inc. Stock 12‑Month Price Target Raised to $13, Implies 105% Upside - TradingView
Taysha Gene Therapies, Inc.(NasdaqGS:TSHA) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Taysha Gene Therapies, Inc.(NasdaqGS: TSHA) dropped from Russell 3000E Index - marketscreener.com
Taysha Gene Therapies, Inc.(NasdaqGS:TSHA) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Taysha Gene Therapies launches $200M public offering; shares down - MSN
Taysha Gene Therapies Inc (TSHA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Taysha Gene Therapies shares tumble following pricing shares at $6.00 to raise $200M - MSN
Form 424B5 Taysha Gene Therapies Inc For: 25 June By Investing.com - Investing.com Nigeria
Taysha Gene Therapies to present Rett syndrome data at conference By Investing.com - Investing.com Nigeria
Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting - Investing News Network
Taysha Gene Therapies to present Rett syndrome data at conference - Investing.com
Taysha Gene Therapies Prices Equity Offering for ~$187.4 Million Net, Grants 5 Million Share Option - TradingView
Taysha Gene Therapies (NASDAQ: TSHA) prices $200M equity raise with warrants - Stock Titan
Taysha Gene Therapies, Inc. to present TSHA-102 Rett syndrome clinical program at scientific meeting - Traders Union
Taysha Gene Therapies (TSHA) priced 32.5M-share offering; $187M net proceeds - Stock Titan
Taysha lines up TSHA-102 data on Rett syndrome at June 29 meeting - Stock Titan
Taysha Gene Therapies Down Over 11%, on Pace for Largest Percent Decrease Since May 2025 -- Data Talk - Moomoo
Taysha Gene Therapies (TSHA) Shares Fall 9.2% Following $200M Pu - GuruFocus
Taysha Gene Therapies, Inc. Actuals & Estimates (NASDAQ:TSHA) - TradingView
H.B. Fuller, Trip.com, Hertz Global And Other Big Stocks Moving Lower In Thursday Pre-Market Session - Benzinga
Taysha Gene Therapies stock tumbles on public offering pricing By Investing.com - Investing.com Australia
TSHA Secures New Offering at Discounted Price - GuruFocus
Taysha Gene Therapies prices $200M stock offering at $6 per share - Investing.com South Africa
Taysha Gene Therapies: Offering Expected to Close on or Abour June 26 >TSHA - Moomoo
Taysha Gene Therapies Prices $200 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Taysha prices $200M offering as closing nears June 26 - Stock Titan
Taysha Gene Therapies Announces Pricing Of Public Offering Of Common Stock And Pre-Funded Warrants - TradingView
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire
Taysha Gene Therapies launches $200 million stock offering - Investing.com UK
Taysha Gene Therapies Inc Files For Mixed Shelf Offering Of Up To $200 MillionSEC Filing - TradingView
Form 424B5 Taysha Gene Therapies Inc For: 24 June By Investing.com - Investing.com Australia
Taysha Gene Therapies stock tumbles on $200M stock offering By Investing.com - Investing.com South Africa
Taysha presents TSHA-102 data at 2026 IRSF Rett Syndrome meeting - scanx.trade
Taysha Gene Therapies (TSHA) files $200M common stock and pre-funded warrants offering - Stock Titan
Taysha Gene Therapies stock tumbles on $200M stock offering - Investing.com
9 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Taysha Gene Therapies prices $200M public offering of common stock - scanx.trade
Taysha Gene Therapies launches $200 million stock offering By Investing.com - Investing.com Australia
Taysha Gene Therapies Inc Stock (TSHA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Taysha Gene Therapies Inc Stock (TSHA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nagendran Sukumar | President and Head of R&D |
Apr 10 '26 |
Sale |
4.46 |
200,000 |
892,000 |
1,136,410 |
0.72%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):